Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
ID: 357284Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357284

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-034.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the "Novel Assays to Address Translational Gaps in Treatment Development" initiative, aimed at advancing neurophysiological measures that can serve as assays for drug and device therapies in mental health research. This funding opportunity encourages collaborative partnerships among neuroscientists to optimize in vivo testing in both preclinical species and humans, with a focus on bridging the gap between preclinical and clinical measures to enhance therapeutic outcomes for mental disorders. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with key deadlines including an application due date of January 21, 2025, and a funding expiration on June 21, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-034.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute of Mental Health (NIMH), invites applications for the "Novel Assays to Address Translational Gaps in Treatment Development" (Funding Opportunity Number PAR-25-034). This initiative aims to advance the development of neurophysiological measures that could serve as assays for drug and device therapies in mental health research. The funding encourages collaborative partnerships among neuroscientists focused on optimizing in vivo testing in both preclinical species and humans. Projects will undergo a two-phase evaluation process: the UG3 phase for feasibility studies and the UH3 phase for testing these assays with pharmacologic manipulations. Key dates include an application due date on January 21, 2025, and a funding expiration on June 21, 2025. Eligible applicants encompass a broad spectrum of organizations, including higher education institutions, nonprofits, and foreign entities. Essential submission guidelines emphasize adherence to detailed instructions for application preparation. Ultimately, this funding opportunity seeks to bridge the gap between preclinical and clinical measures to improve therapeutic outcomes for mental disorders, marking a significant shift in the evaluation of novel treatments.
    Similar Opportunities
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)" aimed at enhancing therapeutic development for mental illnesses. This initiative seeks to establish in vivo neurophysiological and behavioral measures that can serve as assays in the early screening phase of treatment development, focusing on optimizing and evaluating innovative measures that reflect neural processes relevant to both preclinical species and humans. The funding is particularly significant as it addresses critical gaps in the therapeutic development pipeline, with eligible applicants including various educational institutions and organizations, and a budget cap of $250,000 in direct costs per year. Interested parties must submit their applications by February 5, 2025, with a maximum project period of five years, and can direct inquiries to grantsinfo@nih.gov for further information.
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral assays in animal models to enhance the therapeutic development pipeline for mental illnesses, focusing on optimizing measures that reflect clinically relevant brain processes. The program encourages research proposals that assess the sensitivity and specificity of these assays as screening tools and promote collaboration between preclinical and clinical studies to facilitate translation to human applications. Interested applicants can apply for grants up to $250,000, with the application deadline set for September 7, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at fostering the development of innovative brain stimulation devices or enhancing existing FDA-approved devices for treating mental health disorders. The initiative seeks applications from multi-disciplinary teams with expertise in neuroscience, engineering, clinical practices, and regulatory matters, focusing on creating devices that offer improved spatial and temporal resolution compared to current technologies. This funding opportunity is critical for advancing treatment methods in mental health care, with no budget limits as long as costs align with project needs, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Innovation Grants to Nurture Initial Translational Efforts (IGNITE) aimed at developing assays and identifying therapeutic agents for neurological and neuromuscular disorders. This funding opportunity encourages research grant applications focused on assay development and iterative screening to characterize potential therapeutics, operating under the R61/R33 phased award mechanism that requires progression based on achieving specific milestones. The initiative is crucial for advancing scientific knowledge and addressing significant health challenges, with a total estimated program funding of $750,000 and an award ceiling of $750,000. Applications are due starting January 18, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This grant supports projects that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices, focusing on improving spatial and temporal precision and enabling multi-focal approaches for effective treatment delivery. The initiative is crucial for addressing clinical limitations in mental health technologies and encourages collaboration among multidisciplinary teams with expertise in neuroscience, engineering, and regulatory affairs. Interested applicants can apply for up to $275,000 over a two-year project period, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health disorders. This initiative seeks applications that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices through improvements in hardware and software, focusing on increased spatiotemporal precision and multi-focal, closed-loop approaches. The program is particularly important for addressing limitations in current mental health treatments and fostering technological innovation in this field. Interested applicants can apply for grants up to $275,000 for a two-year project period, with applications due by January 7, 2028. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-286.html.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This initiative encourages investigators to engage in translational activities and small clinical studies, focusing on the implementation of clinical prototype devices, non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals for clinical trials. The program emphasizes a milestone-driven approach, requiring collaboration with NIH staff throughout the project, and aims to address health disparities in neurological health. Interested applicants, including various educational and community organizations, must submit their proposals by January 28, 2027, and can find additional information and application guidelines at NIH Grants.